In our study, CCL2 significantly correlated with the severity of human NASH and CCL2 release from ECs was significantly altered by RUNX1 expression, adding novel insight into how RUNX1/CCL2 mediates infiltration of inflammatory cells and angiogenesis in NASH. Here, RUNX1 is linked to metabolic dysfunction-associated steatohepatitis.